JP5025867B2 - 粘膜ＤＴＰａワクチン - Google Patents
粘膜ＤＴＰａワクチン Download PDFInfo
- Publication number
- JP5025867B2 JP5025867B2 JP2001526202A JP2001526202A JP5025867B2 JP 5025867 B2 JP5025867 B2 JP 5025867B2 JP 2001526202 A JP2001526202 A JP 2001526202A JP 2001526202 A JP2001526202 A JP 2001526202A JP 5025867 B2 JP5025867 B2 JP 5025867B2
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- pertussis
- dtpa
- vaccine
- tetanus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 56
- 239000000427 antigen Substances 0.000 claims abstract description 54
- 108091007433 antigens Proteins 0.000 claims abstract description 54
- 102000036639 antigens Human genes 0.000 claims abstract description 54
- 201000005702 Pertussis Diseases 0.000 claims abstract description 38
- 206010013023 diphtheria Diseases 0.000 claims abstract description 15
- 206010043376 Tetanus Diseases 0.000 claims abstract description 14
- 239000000203 mixture Substances 0.000 claims abstract description 14
- 239000003053 toxin Substances 0.000 claims abstract description 13
- 231100000765 toxin Toxicity 0.000 claims abstract description 13
- 108010021711 pertactin Proteins 0.000 claims abstract description 5
- 101710154643 Filamentous hemagglutinin Proteins 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 238000002255 vaccination Methods 0.000 claims description 6
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 claims description 5
- 229960000814 tetanus toxoid Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 abstract description 32
- 102000009016 Cholera Toxin Human genes 0.000 abstract description 12
- 108010049048 Cholera Toxin Proteins 0.000 abstract description 12
- 241000588724 Escherichia coli Species 0.000 abstract description 9
- 238000009472 formulation Methods 0.000 abstract description 8
- 208000015181 infectious disease Diseases 0.000 abstract description 7
- 241000588832 Bordetella pertussis Species 0.000 abstract description 3
- 229940032047 Tdap vaccine Drugs 0.000 abstract 1
- 229930186900 holotoxin Natural products 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 28
- 230000004044 response Effects 0.000 description 23
- 101150026046 iga gene Proteins 0.000 description 14
- 238000007918 intramuscular administration Methods 0.000 description 13
- 210000004072 lung Anatomy 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 102000004388 Interleukin-4 Human genes 0.000 description 11
- 108090000978 Interleukin-4 Proteins 0.000 description 11
- 108010002616 Interleukin-5 Proteins 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 102000004127 Cytokines Human genes 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 10
- 108700012359 toxins Proteins 0.000 description 10
- 102100037850 Interferon gamma Human genes 0.000 description 9
- 108010074328 Interferon-gamma Proteins 0.000 description 9
- 230000005867 T cell response Effects 0.000 description 9
- 229940037003 alum Drugs 0.000 description 9
- 210000001165 lymph node Anatomy 0.000 description 9
- 230000037452 priming Effects 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 230000028993 immune response Effects 0.000 description 8
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 229940066827 pertussis vaccine Drugs 0.000 description 5
- 210000004989 spleen cell Anatomy 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 206010002091 Anaesthesia Diseases 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 230000006052 T cell proliferation Effects 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000008034 disappearance Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 210000004241 Th2 cell Anatomy 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000005875 antibody response Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000017307 interleukin-4 production Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 230000005730 ADP ribosylation Effects 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 108010055044 Tetanus Toxin Proteins 0.000 description 2
- 230000000240 adjuvant effect Effects 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 2
- 229960003132 halothane Drugs 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000022023 interleukin-5 production Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 101710105075 Agglutinin-2 Proteins 0.000 description 1
- 241000186031 Corynebacteriaceae Species 0.000 description 1
- 229940032024 DPT vaccine Drugs 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 102000000743 Interleukin-5 Human genes 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 241001591005 Siga Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- NFXWJYUDIOHFAW-UHFFFAOYSA-N acetic acid;tetradecanoic acid Chemical compound CC(O)=O.CCCCCCCCCCCCCC(O)=O NFXWJYUDIOHFAW-UHFFFAOYSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 229940030156 cell vaccine Drugs 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940001442 combination vaccine Drugs 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229960003983 diphtheria toxoid Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229940100652 nasal gel Drugs 0.000 description 1
- 229940052404 nasal powder Drugs 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000010845 search algorithm Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940118376 tetanus toxin Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/832—Drug, bio-affecting and body treating compositions involving bacterial toxin that has modified amino acid sequence
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/825—Bacteria
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9923060.9 | 1999-09-29 | ||
| GBGB9923060.9A GB9923060D0 (en) | 1999-09-29 | 1999-09-29 | Vaccine |
| PCT/IB2000/001440 WO2001022993A2 (en) | 1999-09-29 | 2000-09-28 | MUCOSAL DTPa VACCINES |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012000806A Division JP2012067137A (ja) | 1999-09-29 | 2012-01-05 | 粘膜ＤＴＰａワクチン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003510292A JP2003510292A (ja) | 2003-03-18 |
| JP2003510292A5 JP2003510292A5 (https=) | 2007-11-15 |
| JP5025867B2 true JP5025867B2 (ja) | 2012-09-12 |
Family
ID=10861826
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001526202A Expired - Fee Related JP5025867B2 (ja) | 1999-09-29 | 2000-09-28 | 粘膜ＤＴＰａワクチン |
| JP2012000806A Withdrawn JP2012067137A (ja) | 1999-09-29 | 2012-01-05 | 粘膜ＤＴＰａワクチン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012000806A Withdrawn JP2012067137A (ja) | 1999-09-29 | 2012-01-05 | 粘膜ＤＴＰａワクチン |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7279169B1 (https=) |
| EP (1) | EP1223975B1 (https=) |
| JP (2) | JP5025867B2 (https=) |
| AT (1) | ATE431744T1 (https=) |
| CA (1) | CA2386023C (https=) |
| CY (1) | CY1110327T1 (https=) |
| DE (1) | DE60042243D1 (https=) |
| DK (1) | DK1223975T3 (https=) |
| ES (1) | ES2323936T3 (https=) |
| GB (1) | GB9923060D0 (https=) |
| PT (1) | PT1223975E (https=) |
| WO (1) | WO2001022993A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9326174D0 (en) * | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
| WO2002080982A2 (en) | 2001-01-12 | 2002-10-17 | Chiron Corporation | Nucleic acid mucosal immunization |
| GB0302218D0 (en) | 2003-01-30 | 2003-03-05 | Chiron Sri | Vaccine formulation & Mucosal delivery |
| NZ536859A (en) * | 2002-05-14 | 2007-11-30 | Chiron Srl | Mucosal combination vaccines for bacterial meningitis |
| AU2010203223B9 (en) | 2009-01-05 | 2015-10-08 | Epitogenesis Inc. | Adjuvant compositions and methods of use |
| AR077636A1 (es) * | 2009-07-08 | 2011-09-14 | Abbott Biologicals Bv | Vacuna viral y uso de la misma |
| CN107837394A (zh) | 2011-06-24 | 2018-03-27 | 埃皮托吉尼西斯有限公司 | 作为抗原特异性免疫调节剂的包含选择的载体、维生素、单宁和类黄酮的组合的药物组合物 |
| JP5966018B2 (ja) * | 2011-12-21 | 2016-08-10 | バイオネット−エイジア，カンパニー・リミテッド | 改変ボルデテラ・パータシス株 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02243633A (ja) * | 1988-04-08 | 1990-09-27 | Kitasato Inst:The | ワクチン製剤 |
| WO1993021950A1 (en) * | 1992-04-28 | 1993-11-11 | Medeva Holdings Bv | Vaccine compositions for mucosal delivery |
| JPH08231422A (ja) * | 1995-02-24 | 1996-09-10 | Chemo Sero Therapeut Res Inst | 混合ワクチン |
| WO1998020734A1 (en) * | 1996-11-14 | 1998-05-22 | The Government Of The United States Of America, As Represented By The Secretary Of The Army | Adjuvant for transcutaneous immunization |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1248735B (it) | 1990-06-21 | 1995-01-26 | Sclavo Spa | Vaccini acellulari contro la pertosse |
| GB9513371D0 (en) | 1995-06-30 | 1995-09-06 | Biocine Spa | Immunogenic detoxified mutant toxins |
| IT1253009B (it) | 1991-12-31 | 1995-07-10 | Sclavo Ricerca S R L | Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini |
| FI945483A7 (fi) | 1992-05-23 | 1995-01-20 | Smithkline Beecham Biologicals S A | Hepatiitti B - pinta-antigeenejä ja muita antigeenejä sisältäviä yhdistelmärokotteita |
| DK0616034T3 (da) * | 1993-03-05 | 2005-02-21 | Wyeth Corp | Plasmid til fremstilling af CRM-protein og diphtheria toxin |
| GB9622133D0 (en) | 1996-10-24 | 1996-12-18 | Niotech Limited | Inverter circuits |
| US7115730B1 (en) * | 1999-04-27 | 2006-10-03 | Chiron Srl | Immunogenic detoxified mutant E. coli LT-A-toxin |
-
1999
- 1999-09-29 GB GBGB9923060.9A patent/GB9923060D0/en not_active Ceased
-
2000
- 2000-09-28 DE DE60042243T patent/DE60042243D1/de not_active Expired - Lifetime
- 2000-09-28 AT AT00962770T patent/ATE431744T1/de active
- 2000-09-28 PT PT00962770T patent/PT1223975E/pt unknown
- 2000-09-28 CA CA2386023A patent/CA2386023C/en not_active Expired - Fee Related
- 2000-09-28 DK DK00962770T patent/DK1223975T3/da active
- 2000-09-28 JP JP2001526202A patent/JP5025867B2/ja not_active Expired - Fee Related
- 2000-09-28 EP EP00962770A patent/EP1223975B1/en not_active Expired - Lifetime
- 2000-09-28 ES ES00962770T patent/ES2323936T3/es not_active Expired - Lifetime
- 2000-09-28 WO PCT/IB2000/001440 patent/WO2001022993A2/en not_active Ceased
- 2000-09-28 US US10/089,367 patent/US7279169B1/en not_active Expired - Fee Related
-
2009
- 2009-08-12 CY CY20091100868T patent/CY1110327T1/el unknown
-
2012
- 2012-01-05 JP JP2012000806A patent/JP2012067137A/ja not_active Withdrawn
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02243633A (ja) * | 1988-04-08 | 1990-09-27 | Kitasato Inst:The | ワクチン製剤 |
| WO1993021950A1 (en) * | 1992-04-28 | 1993-11-11 | Medeva Holdings Bv | Vaccine compositions for mucosal delivery |
| JPH08231422A (ja) * | 1995-02-24 | 1996-09-10 | Chemo Sero Therapeut Res Inst | 混合ワクチン |
| WO1998020734A1 (en) * | 1996-11-14 | 1998-05-22 | The Government Of The United States Of America, As Represented By The Secretary Of The Army | Adjuvant for transcutaneous immunization |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2323936T3 (es) | 2009-07-28 |
| ATE431744T1 (de) | 2009-06-15 |
| EP1223975B1 (en) | 2009-05-20 |
| JP2012067137A (ja) | 2012-04-05 |
| GB9923060D0 (en) | 1999-12-01 |
| PT1223975E (pt) | 2009-08-26 |
| DK1223975T3 (da) | 2009-08-31 |
| CA2386023A1 (en) | 2001-04-05 |
| WO2001022993A2 (en) | 2001-04-05 |
| WO2001022993A3 (en) | 2001-10-25 |
| CA2386023C (en) | 2011-04-26 |
| US7279169B1 (en) | 2007-10-09 |
| CY1110327T1 (el) | 2015-01-14 |
| EP1223975A2 (en) | 2002-07-24 |
| DE60042243D1 (de) | 2009-07-02 |
| JP2003510292A (ja) | 2003-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4283889B2 (ja) | 非毒性の粘膜アジュバント | |
| JP2012067137A (ja) | 粘膜ＤＴＰａワクチン | |
| AU648509B2 (en) | Stable vaccine compositions containing interleukins | |
| JP3911058B2 (ja) | ストレプトコックス エキワクチン | |
| JP2010006827A (ja) | インターロイキン−１２とともに処方された髄膜炎菌のワクチン | |
| US20100008951A1 (en) | Flu vaccine admixture of mannan and flu antigen | |
| US6929794B1 (en) | IL-12 as an adjuvant for Bordetella pertussis vaccines | |
| McCLUSKIE et al. | Immunization against hepatitis B virus by mucosal administration of antigen–antibody complexes | |
| KR102852282B1 (ko) | 면역원성 조성물 | |
| Cahill et al. | Mice are protected against Bordetella pertussis infection by intra-nasal immunization with filamentous haemagglutinin | |
| WO1999040937A2 (en) | Vaccines comprising interleukin-12 and respiratory syncytial viral antigens | |
| JP5148577B2 (ja) | 非毒性の粘膜アジュバント | |
| EP3858382A1 (en) | Mucosal adjuvant | |
| Stratford et al. | A vaccination strategy incorporating DNA priming and mucosal boosting using tetanus toxin fragment C (TetC) | |
| Mohammad Pour-dounighi et al. | Humoral immune response to Diphtheria and Tetanus toxoids by intranasal administration | |
| MXPA00007881A (en) | Vaccines comprising interleukin-12 and respiratory syncytial viral antigens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070926 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070926 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100721 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101012 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110831 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111129 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111206 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120105 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120618 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120620 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150629 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |